Rufus-Membere Pamela, Holloway-Kew Kara L, Diez-Perez Adolfo, Kotowicz Mark A, Pasco Julie A
School of Medicine, Deakin University, Geelong, Victoria, Australia.
Department of Internal Medicine, Hospital del Mar-IMIM, Autonomous University of Barcelona and CIBERFES, Instituto Carlos III, Madrid, Spain.
BMJ Open. 2018 Dec 22;8(12):e023959. doi: 10.1136/bmjopen-2018-023959.
The OsteoProbe measures Bone Material Strength Index (BMSi) of cortical bone in living humans using impact microindentation (IMI). Research using this minimally invasive technique is expanding yet, to-date, there have been no reports about its feasibility in the research setting. In this study, we assessed the feasibility and tolerability of using the OsteoProbe in men enrolled in the Geelong Osteoporosis Study.
Cross-sectional analysis of data collected in a population-based study.
Barwon Statistical Division, southeastern Australia, 2016-2018.
For 252 of 345 consecutive participants (ages 33-96 years), BMSi was measured using the OsteoProbe at the mid-tibia. Immediately following measurement, each participant used a Visual Analogue Scale (0-10) to rate the level of discomfort that was anticipated and experienced, their initial reluctance towards the measurement and their willingness to repeat measurement.
Reasons for non-measurement in 92 men were needle phobia (n=8), discomfort after first indentation (n=5), skin infections (n=21), excessive soft tissues around the mid-tibia region (n=56), inability to provide informed consent (n=2). Among 252 men who had IMI measures, the expectation for pain during measurement was low (1.54±1.56), as was actual pain experienced (0.38±0.71). Reluctance to undergo measurement was low (0.34±0.93). All participants indicated a willingness to have the measurement performed again. Mean (±SD) BMSi was 83.0±6.4 (range 62.3-93.0).
In this study, the procedure was well accepted by participants suggesting that IMI testing with the OsteoProbe is feasible in a research setting.
OsteoProbe通过冲击微压痕法（IMI）测量活体人类皮质骨的骨材料强度指数（BMSi）。使用这种微创技术的研究正在不断扩展，但迄今为止，尚无关于其在研究环境中的可行性的报道。在本研究中，我们评估了在参加吉朗骨质疏松症研究的男性中使用OsteoProbe的可行性和耐受性。
对一项基于人群的研究中收集的数据进行横断面分析。
澳大利亚东南部巴旺统计区，2016 - 2018年。
在345名连续参与者（年龄33 - 96岁）中的252名中，使用OsteoProbe在胫骨中部测量BMSi。测量后，每位参与者立即使用视觉模拟量表（0 - 10）对预期和经历的不适程度、他们最初对测量的抵触情绪以及重复测量的意愿进行评分。
92名男性未进行测量的原因包括针头恐惧症（n = 8）、首次压痕后不适（n = 5）、皮肤感染（n = 21）、胫骨中部区域软组织过多（n = 56）、无法提供知情同意（n = 2）。在进行IMI测量的252名男性中，测量期间对疼痛的预期较低（1.54±1.56），实际经历的疼痛也较低（0.38±0.71）。对接受测量的抵触情绪较低（0.34±0.93）。所有参与者均表示愿意再次进行测量。平均（±标准差）BMSi为83.0±6.4（范围62.3 - 93.0）。
在本研究中，该程序被参与者广泛接受，表明使用OsteoProbe进行IMI测试在研究环境中是可行的。
